Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Enteroabsorbente de amplio espectro de nueva generación

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TORU20151201001
Publicado:
21/12/2015
Caducidad:
21/12/2016
Resumen:
Una compañía farmacéutica rusa especializada en producir medicamentos ha desarrollado un enteroabsorbente de amplio espectro de nueva generación. Este medicamento se emplea para intoxicaciones de diverso origen (incluyendo intoxicación por alcohol), infecciones gastrointestinales, alergias o disbacteriosis. El enteroabsorbente polifuncional se basa en sílice altamente disperso con un tamaño de partículas de hasta 0,09 mm. El medicamento se administra por vía oral en forma de suspensión acuosa y la dosis depende del peso corporal. Se buscan socios con el fin de establecer acuerdos de fabricación y servicio.

Details

Tittle:
The new generation broad spectrum enterosorbent.
Summary:
The Russian pharmaceutical company, which specializes in the production of medicinal drugs, developed a broad spectrum enterosorbent of the new generation. The drug is used for intoxication of various origins (including alcohol), gastrointestinal infections, allergies, disbacteriosis. The company is looking for the partners under the manufacturing agreement and services agreement.
Description:
The Russian pharmaceutical company specializes in the research, development and production of medicinal drugs. The company has developed a new generation broad-spectrum oral enterosorbent. Currently, non-selective sorbents are the drugs of choice in the treatment of toxic food infections and poisoning of different etiologies. Therefore, the basic effectiveness parameters of their usage are the sorption capacity and safety of the body (the level of absorption into the blood, the degree of body demedication). Existing medicinal drugs have little sorption effect, selectivity towards the toxins and their use is limited to the treatment of toxic food infections and diarrheal disorders. The proposed drug is a polyfunctional enterosorbent based on highly dispersed silica having with the particle sizes up to 0.09 mm. The drug dosage form is powder. The drug is taken orally in the form of an aqueous suspension, the dosage depends on the body weight. Passing through the gastrointestinal tract, the drug adsorbs toxins, allergens, radionuclides, alcohol decomposition products, microorganisms and other substances responsible for the occurrence of various diseases. Since the initial development, the drug formula has been optimized. Currently, the spectrum of action of the drug has been enhanced, as confirmed by the patent of the possibilities of its usage: - adaptogen (1992 patent); -antioxidant, membrane stabiliser (2003 patent); - blocker of the alcohol withdrawal syndrome (2006 patent). - antiallergical drug with the detoxification mechanism of action foe dermatoses treatment (2015 patent); Also, the drug is registered throughout the European Union in accordance with the requirements of ISO 13485: 2012 and the European directive MDD 93/42 / EEC. Advantages of the drug compared to the analogues: - High sorption capacity - 300 square meters. m / g (3 times higher); - Intact withdrawal from the body; - No absorption into the blood.
Partners for the manufacturing agreement and services agreement are sought. Under the manufacturing agreement the partner´s tasks are to development the design and approved manufacture of the drug package according to EU ecological requirements. Under the services agreement the partner will be provide the certification of the drug in the EU. All terms of delivery and contract will be discussed after the first contact.
Advantages and Innovations:
The innovative solution is in the know-how used in the manufacture of the stock blend - finely divided silica powder. Unlike the existing drug analogues, the drug has the following advantages:
- High sorption capacity - 300 square meters. m / g (3 times higher in comparison to the analogues).
- Depletion of intoxication, regardless of the cause: food or alcohol poisoning, allergic reaction (the analogs have selective sorption capacity).
- Contributes to overcoming the pharmacological resistance of the body to other drugs.
Stage of Development:
Already on the market
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Russian Federation: 1992, 2003, 2006, 2015

Partner sought

Type and Role of Partner Sought:
Type of partner: SME, R-Y-D.
Field of activity: medicine and pharmaceutics, product certification.
Partner´s role: product certification in EU, design and manufacture of the drug package according to EU ecological standards.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos